Who is sponsoring NCT03239704?

NCT03239704 is sponsored by Mount Sinai Hospital, Canada.

What drugs are being tested in NCT03239704?

Interventions in NCT03239704: Telemedicine Follow-Up, Telemedicine Monitoring, 30 Day Comprehensive Questionnaire.

What condition does NCT03239704 study?

NCT03239704 studies Inflammatory Bowel Disease, Ulcerative Colitis, Crohn Disease.

Is NCT03239704 still recruiting?

NCT03239704 is currently status unknown. Last updated 10 September 2018.

Last reviewed 2018-09-10 · How we verify

NCT03239704

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease

Status unknown NA Last updated 10 September 2018

What this trial tests

NA trial testing Telemedicine Follow-Up in Inflammatory Bowel Disease in 450 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
1 December 2020

1 December 2020

Quick facts

Lead sponsor	Mount Sinai Hospital, Canada
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	450
Start date	1 December 2018
Primary completion	1 December 2020
Estimated completion	1 December 2020
Sites	1 location across Canada

Drugs / interventions tested

Telemedicine Follow-Up
Telemedicine Monitoring
30 Day Comprehensive Questionnaire

Conditions studied

Inflammatory Bowel Disease — all drugs for Inflammatory Bowel Disease →
Ulcerative Colitis — all drugs for Ulcerative Colitis →
Crohn Disease — all drugs for Crohn Disease →

Sponsor

Mount Sinai Hospital, Canada

Who can join

18 and older, any sex, with Inflammatory Bowel Disease or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world - 16.3 and 12.3 per 100,000 for CD and UC respectively. In the absence of a cure, the current goal of treatment is to manage patients in a milder state of remission. However, maintaining (or even achieving) remission is dependent on timely access to specialist IBD care; which in light of rising incidence rates have proven to be challenging. Moreover, patients often experience flare-ups of their gastrointestinal symptoms, while awaiting access to specialist care. In recent years, there has been increased integration of telemedicine services in gastroenterology practice. This change has been driven by a desire among IBD patients to have more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person consultations. Within the context of IBD, telemedicine might be effective in delivering routine and timely follow-up care to high-risk patients. The purpose of this study to determine whether telemedicine-based follow-up care can effectively manage the gastrointestinal symptoms of high-risk IBD patients and reduce their need for preventive health care services.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Disease

Currently open trials in the same condition.

NCT07210580 — Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory · NA · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
NCT07252427 — Gut Microbiota in IBD With Comorbid Depressive Disorder · recruiting
NCT06781827 — Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease · NA · recruiting

Other Mount Sinai Hospital, Canada trials

Trials by the same sponsor.

NCT07272460 — Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial · NA · recruiting
NCT07046572 — Methoxyflurane for IUD Insertion and Endometrial Biopsy · NA · recruiting
NCT06504277 — Low Versus Standard Pressure Pneumoperitoneum on Shoulder Tip Pain · NA · recruiting
NCT06546254 — 1% Lidocaine Paracervical Block for Endometrial Biopsy · NA · completed
NCT06733701 — The Use of Virtual Reality Technology During Oocyte Retrieval for in Vitro Fertilization · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03239704 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mount Sinai Hospital, Canada
Last refreshed: 10 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03239704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing